Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Galapagos CFO and COO Thad Huston Departs August 1 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Galapagos CFO and COO Thad Huston Departs August 1

Huston has decided to leave the company and return to the U.S. for personal and professional reasons.

By: Rachel Klemovitch

Assistant Editor

Galapagos NV, a global biotechnology company, announced the departure of its CFO and COO, Thad Huston, effective as of August 1, 2025. The company expects to announce Huston’s successor in the coming months.

Huston joined Galapagos NV in 2023 from Kite Pharma, Inc., to support Galapagos’ transformation into a cell therapy company. Huston has decided to leave the company and return to the U.S. for personal and professional reasons.

Paul Stoffels, MD, CEO and Chair of the Board of Directors of Galapagos, said, “Over the past two years, Thad has worked on the transformation of Galapagos into a focused cell therapy business leveraging our unique decentralized cell therapy platform to deliver fresh, stem-like early memory CAR-T therapy with a vein-to-vein time of seven days. Thad will remain with the company until August 1, 2025, to ensure a smooth handover of responsibilities.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters